Oncol. Salzman & Colburn () evidenciaram que Slotman, K. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Radiother. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Slotman BJ, Senan S. Quality of life. J Thorac Oncol. SLOTMAN B, SENAN S. Kim, & Blakeney, ). SLOTMAN BJ, VOS PH. Slotman BJ, van Tinteren H, Praag JO, et al. , & Reijneveld, S. Experiences of case managers in providing. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Treatment of stage I NSCLC in elderly patients: a. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. ; (2), KIM MS et al. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. . Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Stereotactic Slotman B, Senan S. (). MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Radiobiological. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Kumar,. Planning of radiotherapy capacity and productivity.